Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 11, 2016, Pages 3206-3211

  Floridia, Marco ^a   Liotta, Giuseppe ^b   Andreotti, Mauro ^a   Galluzzo, Clementina M ^a   Amici, Roberta ^a   Jere, Haswell ^c   Sagno, Jean Baptiste ^c   Marazzi, Maria C ^d   Buonomo, Ersilia ^b   Scarcella, Paola ^b   Mancinelli, Sandro ^b   Vella, Stefano ^a   Giuliano, Marina ^a   Palombi, Leonardo ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c DREAM Program   (Malawi)

^d LUMSA UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; EFAVIRENZ; LAMIVUDINE; TENOFOVIR; ALKALINE PHOSPHATASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ARTICLE; BODY HEIGHT; BONE GROWTH; BONE METABOLISM; BREAST FEEDING; CONTROLLED STUDY; FEMALE; GROWTH RETARDATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALAWI; MALE; OSSIFICATION; OSTEOLYSIS; PERINATAL DRUG EXPOSURE; PREGNANCY; PRENATAL DRUG EXPOSURE; ADULT; BLOOD; CHEMICALLY INDUCED; HIV INFECTIONS; NEWBORN; PREVENTION AND CONTROL; VERTICAL TRANSMISSION; YOUNG ADULT;

ADULT; ALKALINE PHOSPHATASE; ANTI-HIV AGENTS; BENZOXAZINES; BIOMARKERS; BONE RESORPTION; BREAST FEEDING; COLLAGEN TYPE I; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MALAWI; MALE; PEPTIDES; PREGNANCY; TENOFOVIR; YOUNG ADULT;

EID: 84994497543     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw268     Document Type: Article

References (36)

1. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Geneva, Switzerland: WHO, 2013.
2. O'Brien L, Shaffer N, Sangrujee N et al. The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV. Bull World Health Organ 2014; 92: 162-70.
3. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31. July 2015. Wilmington, NC, USA: Registry Coordinating Center, 2014. http://www.apregistry.com/InterimReport.aspx.
4. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25: 2301-4.
5. Brown TT, Ross AC, Storer N et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus nontenofovir regimens. Antivir Ther 2011; 16: 1063-72.
6. Cotter AG, Vrouenraets SM, Brady JJ et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 2013; 98: 1659-66.
7. Assoumou L, Katlama C, Viard JP et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS 2013; 27: 2425-30.
8. Scherzer R, Estrella M, Li Y et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-75.
9. Best BM, Burchett S, Li H et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med 2015; 16: 502-11.
10. Himes SK, Wu JW, Jacobson DL et al. Meconium tenofovir concentrations and growth and bone outcomes in prenatally tenofovir exposed HIV-uninfected children. Pediatr Infect Dis J 2015; 34: 851-7.
11. Benaboud S, Pruvost A, Coffie PA et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-infected women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TemAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315-7.
12. Mirochnick M, Taha T, Kreitchmann R et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65: 3-41.
13. Viganò A, Mora S, Giacomet V et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16: 1259-66.
14. Gibb DM, Kizito H, Russell EC et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9: e1001217.
15. Ransom CE, Huo Y, Patel K et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64: 374-81.
16. Siberry GK, Williams PL, Mendez H et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26: 1151-9.
17. Siberry GK, Jacobson DL, Kalkwarf HJ et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015; 61: 996-1003.
18. Kim MH, Ahmed S, Hosseinipour MC et al. The impact of option B+ on the antenatal PMTCT cascade in Lilongwe, Malawi. J Acquir Immune Defic Syndr 2015; 68: 77-83.
19. WHO. WHO Anthro, Version 3.2.2, January 2011. http://www.who.int/childgrowth/software/en/.
20. Tsai KS, Jang MH, Hsu SH et al. Bone alkaline phosphatase isoenzyme and carboxy-terminal propeptide of type-I procollagen in healthy Chinese girls and boys. Clin Chem 1999; 45: 136-8.
21. TECOmedical Group. TECOmedical Clinical and Technical Review: Bone Alkaline Phosphatase. A Biochemical Marker of Bone Turnover. January 2013 http://www.tecomedical.com/en/clinical-information.
22. Crofton PM, Evans N, Taylor MR et al. Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin Chem 2002; 48: 671-3.
23. Giuliano M, Andreotti M, Liotta G et al. Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. PLoS One 2013; 8: e68950.
24. Pettifor JM. Nutritional rickets: pathogenesis and prevention. Pediatr Endocrinol Rev 2013; 10 (Suppl 2): 347-53.
25. Yang L, Grey V. Pediatric reference intervals for bone markers. Clin Biochem 2006; 39: 561-8.
26. Huang Y, Eapen E, Steele S et al. Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 2011; 44: 771-8.
27. Namgung R, Tsang RC. Bone in the pregnant mother and newborn at birth. Clin Chim Acta 2003; 333: 1-11.
28. Fischer DC, Mischek A, Wolf S et al. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bonespecific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 2012; 49: 546-53.
29. Mora S, Giacomet V, Viganò A et al. Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone 2012; 50: 255-8.
30. Doherty CP, Crofton PM, Sarkar MA et al. Malnutrition, zinc supplementation and catch-up growth: changes in insulin-like growth factor I, its binding proteins, bone formation and collagen turnover. Clin Endocrinol 2002; 57: 391-9.
31. Amukele TK, Soko D, Katundu P et al. Vitamin D levels in Malawian infants from birth to 24 months. Arch Dis Child 2013; 98: 180-3.
32. Thiering E, Brüske I, Kratzsch J et al. Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. Sci Rep 2015; 5: 18138.
33. Czech-Kowalska J, Pludowski P, Dobrzanska A et al. Impact of vitamin D supplementation on markers of bone mineral metabolism in term infants. Bone 2012; 51: 781-6.
34. Purdy JB, Gafni RI, Reynolds JC et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152: 582-4.
35. Gafni RI, Hazra R, Reynolds JC et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118: e711-8.
36. Palombi L, Pirillo MF, Marchei E et al. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. J Antimicrob Chemother 2016; 71: 1027-30.